All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What are the key considerations for CAR T-cell therapy in elderly patients with lymphoma?
Featured
During the EHA 2022 Congress, the Lymphoma Hub spoke with Anna Sureda, Catalan Institute of Oncology, Barcelona, ES. We asked, What are the key considerations for CAR T-cell therapy in elderly patients with lymphoma?
What are the key considerations for CAR T-cell therapy in elderly patients with lymphoma?
Sureda outlines the phase III prospective randomized study ZUMA-7, which compared axicabtagene ciloleucel versus standard-of-care second-line therapy in adult patients with relapsed/refractory large B-cell lymphoma. Sureda discusses efficacy, safety, and toxicity results, highlighting that the primary endpoint was met.
More about...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox